HeartWare International is facing FDA ire for its ventricular assist system, but regulatory pushback hasn't seemed to put a damper on earnings. The company charted double-digit growth during the second quarter, fueled in part by record sales for its signature device in domestic and international markets.
Quintiles hit the $1 billion revenue mark for a third straight quarter, dialing up its full-year guidance as it expands its share of the global outsourcing market.
3D Systems missed Wall Street earnings expectations because of product delays. The newly disclosed acquisition of Simbionix by 3D Systems for $120 million in cash went largely unnoticed as a consequence; the deal is designed to add 3D virtual reality surgical simulation capabilities to the 3D printer.
Catalent came through with the biggest life sciences IPO of what's shaping up to be a record year, pulling in $871.3 million in a blockbuster Wall Street debut.
While medical device venture activity may have picked up this year, the comparison point in 2013 was abysmally low. In addition, Series A device investment was still shrinking. That's according to a new report from Silicon Valley Bank. These trends are pushing the sector to be more reliant on angel investors, which are becoming more accessible with the advent of crowdfunding, and corporate VCs, who are stealthy but increasingly active.
AstraZeneca CEO Pascal Soriot talked to analysts and reporters for hours Thursday, touting his company's unexpectedly strong second-quarter results. And they were worth touting. But make no mistake: Soriot's remarks were meant for a different audience.
See Sanofi's second-quarter results? You'll notice a spark of new life at the French drugmaker, which hiked its forecast for the year, thanks to stalwart diabetes meds, fast-growing rare disease products, an emerging markets recovery, and solid action in consumer health.
Long cleared by the FDA, Zeltiq Aesthetics' fat-freezing CoolSculpting technology gained enough traction last quarter to catapult the company to a surprise profit. The company was so confident, it also raised its 2014 guidance.
Devices and software aren't a huge part of Hospira's revenues, but they do comprise the worst performing growth segment within the company. To help turn this around, the company announced a plan to streamline and update its device offerings in May 2013; it's now about halfway to the completion anticipated during the second half of 2015.
Edwards Lifesciences stock soared 10% this morning on the back of a strong quarter, highlighted by the $750 million upfront payment it received from Medtronic to settle a patent dispute over the companies' competing artificial valves aimed at patients too frail to undergo open heart surgery.